Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Jakob Michael Riedl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5144-4715; OpenAlex author ID A5001392319. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2020: 4 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. Co-author DOI 10.1158/1078-0432.ccr-25-1788↗
  2. Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? Last author DOI 10.21203/rs.3.rs-4461811/v1↗
  3. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Co-author DOI 10.1055/a-1548-4847↗
  4. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Co-author DOI 10.1016/j.ejca.2021.03.040↗
  5. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Co-author DOI 10.1002/cam4.3233↗
  6. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc anal… Co-author DOI 10.1177/1758835919900872↗
  7. Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051154↗
  8. The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers12071798↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Armin Gerger · 7 shared papers, 2020–2024 · strength 0.82
  2. Konstantin Schlick · 5 shared papers, 2020–2024 · strength 0.64
  3. Michael Stotz · 5 shared papers, 2020–2022 · strength 0.53
  4. Martin Pichler Pichler · 5 shared papers, 2020–2022 · strength 0.53
  5. Dominik Andreas Barth · 5 shared papers, 2020–2022 · strength 0.53
  6. Richard Greil · 4 shared papers, 2020–2024 · strength 0.52
  7. Peter Kornprat · 3 shared papers, 2020 · strength 0.30
  8. Eva Valentina Klocker · 3 shared papers, 2020 · strength 0.30
  9. Qingxiang Lin · 1 shared paper, 2026 · strength 0.27
  10. Andrew Scott Liss · 1 shared paper, 2026 · strength 0.27
  11. Ryan Bruce Corcoran · 1 shared paper, 2026 · strength 0.27
  12. Florian Moik · 2 shared papers, 2021–2022 · strength 0.23
  13. Lukas Weiß · 1 shared paper, 2024 · strength 0.21
  14. Cihan Ay · 1 shared paper, 2022 · strength 0.12
  15. Eva Asamer · 1 shared paper, 2020 · strength 0.10
  16. Joanna Szkandera · 1 shared paper, 2020 · strength 0.10
  17. Wolfgang Eisterer · 1 shared paper, 2020 · strength 0.08
  18. Gerald W. Prager · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.